Compare TG Therapeutics Inc (TGTX) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VanEck Vietnam ETF — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while VanEck Vietnam ETF trades at $17.88. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VNM | |
|---|---|---|
Market Cap | $8.53B | — |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $19.80 |
52-Week Low | $26.94 | $16.34 |
Enterprise Value | $8.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
VNM trades at $17.91, down 1.38% for the day, with a technical outlook leaning bearish based on moving averages. The ETF's performance is challenged by its heavy concentration in Vietnamese real estate and financials, exposing it to sector-specific volatility. Recent news highlights underperformance relative to other emerging markets, though potential exists from FTSE Russell's upcoming EM reclassification in September 2026, which may attract foreign institutional flows.
The outlook remains cautious due to near-term headwinds from sector concentration and macroeconomic factors in Vietnam. Investment opportunity hinges on the country's long-term growth trajectory and potential inflows from index changes, but risks from interest rate sensitivity and concentrated holdings warrant careful consideration for investors seeking emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
